Heavy Forecast

Is it difficult to predict human reactions through animal experiments?

High investment in drug development but low success rate?

Is the experimental data difficult to replicate and meet regulatory requirements?

InFDAUnder the new policies of global regulatory agencies, organ chips are becoming an important tool to replace some animal experiments and improve the predictability of drug development.

This time, we bring you a focus on microfluidic and organ chip applications3Hourly high-density special live broadcast:

《FDAUnder the Roadmap: Organ Chips Empower Drug Development and Disease Research

2025year9moon24Day (next Wednesday)13:30-16:35

Xiao'e Tong live streaming platform, scan the code to make an appointment directly

If you are from:

1. Pharmaceutical and biotechnology companies (drug discovery, preclinical research, toxicology, pharmacology departments)

2. Universities/Frontier Academic Laboratory of the Research Institute (Organ Chips, Organoids, Tumors, Neurology, Nanodrug Delivery)

3. Clinical translational and diagnostic development institutions (tertiary hospital translational medicine centersIVDCompany)

And care about the following issues

How to use organ chips to reduce animal experiments and improve the success rate of new drug development?

How to achieve standardized and reproducible experimental procedures in microfluidics?

How to obtain high connotation cell phenotype data to support new drug decision-making?

4. Models of organoids and diseasesFDAThe real application prospects under the new policy?

So, this live stream is tailor-made for you

Four keynote speeches | Focusing on core pain points and cutting-edge practices

From the forefront of scientific research to business decision-making: the dual value and implementation path of organ chips under global regulatory changes | Luo Chencheng | Diancheng Biotechnology Engineer

The experiment of replacing human drugs with organ chips10Annual Technical Roadmap | Peng Xingyue | Professor at Xiamen University

FDANew Policies and3Step completion1The practical application of key forming organoids in drug development | Han Xinxin | Founder of Lisheng Biology, Ph.D&CEO

Beyond Static Cultivation: A New Paradigm for Building Dynamic Human Thrombosis Models on ChipsTony Palu｜ IrelandCellix

Heavy guest lineup

Point into Biology

Diancheng Biotechnology is a company specializing in one-stop solutions for the fields of biology and medicine (formerly known as Hongke Biotechnology Division). Supported by more than a decade of technological accumulation and customer base in the fields of medicine, biology, and healthcare, we focus on providing one-stop solutions for pharmaceutical companies, biotechnology companies, medical institutions, universities, and research institutions, serving from basic research to sample analysis, and the entire lifecycle of drugs to ensure quality and safety.

The main business scope covers: pharmaceutical supply chain environmental monitoring, temperature verification, life science instruments, laboratory equipment, medical equipment, and moreGxPCompliance consulting and services, etc.

We have deep and long-term technical cooperation with world-class multinational corporations and instrument manufacturing centers, committed to providing customers with innovative solutions. By continuously innovating and providing professional services, we help our clients ensure accurate and reliable monitoring, validation, and experimentation processes100%Compliance. Our clients include companies and institutions such as Roche, Pfizer, Sanofi, Baxter, Lanzhou Biotech, Sinovac, Fosun Pharma, Lonza, BeiGene, WuXi AppTec, West China Hospital, Xiangya Hospital, Peking University, Tsinghua University, etc.

We are committed to safeguarding the quality and safety of drugs and the development of biotechnology, promoting the development of the healthcare industry, and facilitating the realization of a world with highly developed drug safety and medical technology.